Literature DB >> 19561479

Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins.

Jonathan Hernandez1, John Mullinax, Whalen Clark, Paul Toomey, Desiree Villadolid, Connor Morton, Sharona Ross, Alexander Rosemurgy.   

Abstract

OBJECTIVE: This study was undertaken to determine the survival benefit of extending resections to obtain microscopically negative margins after positive intraoperative frozen sections. SUMMARY BACKGROUND DATA: The impact of residual microscopic disease after pancreaticoduodenectomy is currently a point of controversy. It is, however, generally believed that microscopically positive margins negatively impact survival and this may be improved by ultimately achieving negative margins.
METHODS: Since 1995, patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma have been prospectively followed. Margin status has been codified as macro/microscopically negative (R0) or macroscopically negative/microscopically positive (R1). The impact of margin status on survival was evaluated utilizing survival curve analysis. Data are presented as median, mean +/- SD where appropriate.
RESULTS: For pancreatic adenocarcinoma, 202 patients underwent pancreaticoduodenectomy. R0 resections were achieved in 158 patients, 17 of whom required extended resections to achieve complete tumor extirpation after an initially positive intraoperative frozen section (R1 --> R0). R1 resections were undertaken in 44 patients. Median survival for patients undergoing R0 resections was 21 months, 26 +/- 23.4 months versus 13 months, 17 +/- 21.0 months for patients undergoing R1 resections (P = 0.02). Median survival for patients undergoing R1 --> R0 resections was 11 months, 16 +/- 17.3, (P = 0.001). Margin status had a significant correlation with "N" stage and AJCC stage but not "T" stage.
CONCLUSION: Survival after pancreaticoduodenectomy is not improved by extending pancreatic resections to achieve negative margins after initially positive intraoperative frozen sections. Tumor-specific factors beyond the presence of disease at a surgical margin are responsible for the abbreviated survival seen in patients undergoing R1 resections.

Entities:  

Mesh:

Year:  2009        PMID: 19561479     DOI: 10.1097/SLA.0b013e3181ad655e

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection.

Authors:  Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins
Journal:  HPB (Oxford)       Date:  2012-01-19       Impact factor: 3.647

2.  Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma?

Authors:  Jae P Jung; Mazen S Zenati; Ahmad Hamad; Melissa E Hogg; Richard L Simmons; Amer H Zureikat; Herbert J Zeh; Brian A Boone
Journal:  HPB (Oxford)       Date:  2018-11-28       Impact factor: 3.647

3.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

4.  Surgical management of adenocarcinoma of the pancreatic uncinate process in a cancer hospital in egypt.

Authors:  Sameh Roshdy; Osama Hussein; Ahmed Abdallah; Khaled Abdel-Wahab; Ahmed Senbel
Journal:  Clin Med Insights Gastroenterol       Date:  2015-01-14

5.  Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Yaojun Zhang; Adam E Frampton; Patrizia Cohen; Charis Kyriakides; Jan J Bong; Nagy A Habib; Duncan R C Spalding; Raida Ahmad; Long R Jiao
Journal:  J Gastrointest Surg       Date:  2012-08-10       Impact factor: 3.452

6.  Recent advances and limitations of surgical treatment for pancreatic cancer.

Authors:  Keiichi Kubota
Journal:  World J Clin Oncol       Date:  2011-05-10

Review 7.  A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma.

Authors:  James R Butler; Syed A Ahmad; Matthew H Katz; Jessica L Cioffi; Nicholas J Zyromski
Journal:  HPB (Oxford)       Date:  2016-02-01       Impact factor: 3.647

Review 8.  Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground.

Authors:  Stefano Crippa; Giulio Belfiori; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Updates Surg       Date:  2021-07-31

9.  An anatomical-based mapping analysis of the pancreaticoduodenectomy retroperitoneal margin highlights the urgent need for standardized assessment.

Authors:  Vlad Maksymov; Michael Hogan; Mahmoud A Khalifa
Journal:  HPB (Oxford)       Date:  2012-09-21       Impact factor: 3.647

10.  Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.

Authors:  Tomar Ghansah; Nasreen Vohra; Kathleen Kinney; Amy Weber; Krithika Kodumudi; Gregory Springett; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  Cancer Immunol Immunother       Date:  2013-04-19       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.